In August 2024, Kansai Medical University was selected for the MEXT initiative “Program for Developing Core Centers for Advanced Medical Human Resources.” Within our chosen project, “Training Advanced Medical Professionals to Promote Cutting-edge Cancer Clinical Research and Optimize Personalized Medicine,” the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service plays a central role.
This initiative aims to establish a distinctive clinical research hub focused on overcoming Japan’s drug loss and drug lag. Through this effort, we seek to cultivate outstanding physicians with advanced knowledge and skills in clinical education and research, thereby contributing to Japan’s clinical research and the development of medical science and healthcare.
Our goal is to form a core center dedicated to training the next generation of leaders in oncology drug development, who will possess a strong international perspective and be capable of addressing the growing societal demand for innovative cancer therapies.